StockNews.com Begins Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP)

StockNews.com assumed coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research note issued to investors on Monday morning. The firm issued a sell rating on the stock.

Tonix Pharmaceuticals Stock Performance

NASDAQ TNXP opened at $11.50 on Monday. The company has a market cap of $21.51 million, a PE ratio of 0.00 and a beta of 2.07. The stock’s 50 day simple moving average is $29.24 and its 200-day simple moving average is $25.22. Tonix Pharmaceuticals has a 1-year low of $10.82 and a 1-year high of $1,248.00. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($23.00) EPS for the quarter, topping analysts’ consensus estimates of ($203.00) by $180.00. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The firm had revenue of $2.82 million for the quarter, compared to the consensus estimate of $2.63 million. As a group, equities research analysts anticipate that Tonix Pharmaceuticals will post -1762.5 EPS for the current fiscal year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

A number of institutional investors have recently modified their holdings of TNXP. Geode Capital Management LLC grew its stake in shares of Tonix Pharmaceuticals by 1,600.1% in the fourth quarter. Geode Capital Management LLC now owns 1,971,894 shares of the company’s stock valued at $650,000 after buying an additional 1,855,907 shares in the last quarter. PFG Investments LLC acquired a new position in Tonix Pharmaceuticals during the 4th quarter worth $72,000. Finally, Commonwealth Equity Services LLC acquired a new position in Tonix Pharmaceuticals during the 4th quarter worth $40,000. 82.26% of the stock is owned by institutional investors and hedge funds.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.